{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:47:25Z","timestamp":1785890845378,"version":"3.56.0"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this review is to evaluate which psychedelics have the most efficacy data to support their use in the treatment of posttraumatic stress disorder (PTSD). This review also aims to assess safety data and concerns related to psychedelic therapies and identify demographic characteristics that may influence clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A systematic review of the literature was conducted on PubMed, Web of Science, and Scopus to identify randomized controlled studies evaluating the use of psychedelic therapy in treatment of PTSD. Thirteen studies met our inclusion criteria and were included in the review. Six studies evaluated 3,4-methylenedioxymethamphetamine (MDMA)\u2013assisted psychotherapy, while 7 studies evaluated ketamine. Study findings regarding efficacy were mixed. Four of the 6 studies evaluating MDMA-assisted psychotherapy demonstrated statistically significant improvement in PTSD symptoms, while 3 of the 7 studies evaluating intravenous ketamine (ketamine IV) demonstrated statistically significant efficacy (eg, reduced PTSD symptoms, durable effect) in relation to comparators. Both therapies were generally well tolerated. The majority of studies were conducted in primarily civilian populations, with one MDMA study and 2 ketamine IV studies focused on veterans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under supervision may lead to improvements in PTSD symptoms, with the medications being generally well tolerated. However, caution should be used when interpreting study results due to limitations such as treatment expectancy effect and the potential for inadequate blinding. Randomized controlled studies of other psychedelics (eg, psilocybin, lysergic acid diethylamide) are needed to assess their utility in PTSD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag062","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:47:41Z","timestamp":1772628461000},"page":"822-834","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and risks of psychedelics in the treatment of posttraumatic stress disorder: A systematic review"],"prefix":"10.1093","volume":"83","author":[{"given":"Jennifer E","family":"Thomas","sequence":"first","affiliation":[{"name":"Larkin University College of Pharmacy , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dellarole","sequence":"additional","affiliation":[{"name":"Larkin University School of Physician Assistant Studies , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Caballero","sequence":"additional","affiliation":[{"name":"University of Georgia College of Pharmacy , Athens, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026080419562111400_zxag062-B1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision","author":"American Psychiatric Association","year":"2022"},{"key":"2026080419562111400_zxag062-B2","doi-asserted-by":"crossref","DOI":"10.7249\/RR1695","volume-title":"Department of Defense Health Related Behaviors Survey (HRBS): Results for the Reserve Component","author":"Meadows","year":"2018"},{"key":"2026080419562111400_zxag062-B3","doi-asserted-by":"crossref","DOI":"10.7249\/RR1695","volume-title":"Department of Defense Health Related Behaviors Survey (HRBS): Results for the Active Component","author":"Meadows","year":"2018"},{"issue":"6","key":"2026080419562111400_zxag062-B4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jts.23049","article-title":"State of the science: treatment of comorbid posttraumatic stress disorder and substance use disorders","volume":"37","author":"Back","year":"2024","journal-title":"J Trauma Stress"},{"issue":"8","key":"2026080419562111400_zxag062-B5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00127-016-1208-5","article-title":"The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III","volume":"51","author":"Goldstein","year":"2016","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"3","key":"2026080419562111400_zxag062-B6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jts.21814","article-title":"The co-occurrence of major depressive disorder among individuals with posttraumatic stress disorder: a meta-analysis","volume":"26","author":"Rytwinski","year":"2013","journal-title":"J Trauma Stress"},{"issue":"8","key":"2026080419562111400_zxag062-B7","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.chiabu.2014.01.017","article-title":"Comorbidity of PTSD in anxiety and depressive disorders: prevalence and shared risk factors","volume":"38","author":"Spinhoven","year":"2014","journal-title":"Child Abuse Negl"},{"key":"2026080419562111400_zxag062-B8","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition","author":"American Psychiatric Association","year":"2013"},{"key":"2026080419562111400_zxag062-B9","author":"Mann","year":"2025"},{"issue":"3","key":"2026080419562111400_zxag062-B10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/da.20292","article-title":"Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder","volume":"25","author":"Strawn","year":"2008","journal-title":"Depress Anxiety"},{"issue":"5","key":"2026080419562111400_zxag062-B11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0301-0082(93)90035-q","article-title":"Regulation of the hypothalamic corticotropin-releasing hormone neurosecretory system","volume":"40","author":"Whitnall","year":"1993","journal-title":"Prog Neurobiol"},{"issue":"3","key":"2026080419562111400_zxag062-B12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.31887\/DCNS.2011.13.2\/jsherin","article-title":"Post-traumatic stress disorder: the neurobiological impact of psychological trauma","volume":"13","author":"Sherin","year":"2011","journal-title":"Dialogues Clin Neurosci"},{"key":"2026080419562111400_zxag062-B13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-pharmtox-010818-021701","article-title":"The neurobiology and pharmacotherapy of posttraumatic stress disorder","volume":"59","author":"Abdallah","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026080419562111400_zxag062-B14"},{"key":"2026080419562111400_zxag062-B15"},{"issue":"2","key":"2026080419562111400_zxag062-B16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pnpbp.2008.12.004","article-title":"Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review","volume":"33","author":"Berger","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2026080419562111400_zxag062-B17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.brat.2015.10.001","article-title":"Early in-session predictors of response to trauma-focused cognitive therapy for posttraumatic stress disorder","volume":"75","author":"Brady","year":"2015","journal-title":"Behav Res Ther"},{"issue":"4","key":"2026080419562111400_zxag062-B18","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/jts.22812","article-title":"Evidence-based posttraumatic stress disorder treatment in a community sample: military-affiliated versus civilian patient outcomes","volume":"35","author":"Jacoby","year":"2022","journal-title":"J Trauma Stress"},{"issue":"4","key":"2026080419562111400_zxag062-B19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.31486\/toj.23.0076","article-title":"Efficacy and safety of psychedelics in treating anxiety disorders","volume":"23","author":"Feulner","year":"2023","journal-title":"Ochsner J"},{"issue":"2","key":"2026080419562111400_zxag062-B20","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1111\/ejn.16421","article-title":"Psychedelic therapy in depression and substance use disorders","volume":"60","author":"Korkmaz","year":"2024","journal-title":"Eur J Neurosci"},{"issue":"9","key":"2026080419562111400_zxag062-B21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.rec.2021.07.010","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"74","author":"Page","year":"( ). 2021","journal-title":"Rev Esp Cardiol"},{"key":"2026080419562111400_zxag062-B22","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"2026080419562111400_zxag062-B23","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"2026080419562111400_zxag062-B24","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2026080419562111400_zxag062-B25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"2026080419562111400_zxag062-B26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of \u00b13,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2026080419562111400_zxag062-B27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (\u00b13,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J Psychopharmacol"},{"issue":"12","key":"2026080419562111400_zxag062-B28","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/0269881118806297","article-title":"3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial","volume":"32","author":"Ot'alora","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"3","key":"2026080419562111400_zxag062-B29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4103\/2542-3932.211589","article-title":"Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy prolong the therapeutic effects of single ketamine infusion on post-traumatic stress disorder and comorbid depression: a pilot randomized, placebo-controlled, cross-over clinical trial","volume":"2","author":"Pradhan","year":"2017","journal-title":"Asia Pac J Clin Trials Nerv Syst Dis"},{"issue":"8","key":"2026080419562111400_zxag062-B30","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41386-022-01266-9","article-title":"Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial","volume":"47","author":"Abdallah","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"2026080419562111400_zxag062-B31","doi-asserted-by":"publisher","first-page":"2470547020981670","DOI":"10.1177\/2470547020981670","article-title":"Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: a randomized double-blind clinical trial","volume":"4","author":"Dadabayev","year":"2020","journal-title":"Chronic Stress (Thousand Oaks)"},{"issue":"11","key":"2026080419562111400_zxag062-B32","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s41386-023-01606-3","article-title":"Long term structural and functional neural changes following a single infusion of ketamine in PTSD","volume":"48","author":"Duek","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"2026080419562111400_zxag062-B33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder","volume":"178","author":"Feder","year":"2021","journal-title":"Am J Psychiatry"},{"issue":"6","key":"2026080419562111400_zxag062-B34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"2026080419562111400_zxag062-B35","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.bbapap.2018.03.006","article-title":"D-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: a pilot study","volume":"1866","author":"Pradhan","year":"2018","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"issue":"3","key":"2026080419562111400_zxag062-B36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/02791072.2008.10400637","article-title":"MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder","volume":"40","author":"Bouso","year":"2008","journal-title":"J Psychoactive Drugs"},{"key":"2026080419562111400_zxag062-B37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1749-6632.2000.tb05199.x","article-title":"Pharmacology of MDMA in humans","volume":"914","author":"de la Torre","year":"2000","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"2026080419562111400_zxag062-B38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/0269881120920420","article-title":"Beyond ecstasy: alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy","volume":"35","author":"Oeri","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"5","key":"2026080419562111400_zxag062-B39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/17425255.2020.1749262","article-title":"MDMA interactions with pharmaceuticals and drugs of abuse","volume":"16","author":"Papaseit","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"pt A","key":"2026080419562111400_zxag062-B40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","article-title":"MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms?","volume":"84","author":"Feduccia","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"11","key":"2026080419562111400_zxag062-B41","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/scan\/nst161","article-title":"MDMA enhances emotional empathy and prosocial behavior","volume":"9","author":"Hysek","year":"2014","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"3","key":"2026080419562111400_zxag062-B42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/02698811211069124","article-title":"A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults","volume":"36","author":"Maples-Keller","year":"2022","journal-title":"J Psychopharmacol"},{"key":"2026080419562111400_zxag062-B43","doi-asserted-by":"publisher","first-page":"906639","DOI":"10.3389\/fphar.2022.906639","article-title":"Effects of 3,4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects","volume":"13","author":"Vizeli","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"2026080419562111400_zxag062-B44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41398-019-0368-y","article-title":"Assessment of fear and anxiety associated behaviors, physiology and neural circuits in rats with reduced serotonin transporter (SERT) levels","volume":"9","author":"Johnson","year":"2019","journal-title":"Transl Psychiatry"},{"issue":"5580","key":"2026080419562111400_zxag062-B45","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.1071829","article-title":"Serotonin transporter genetic variation and the response of the human amygdala","volume":"297","author":"Hariri","year":"2002","journal-title":"Science"},{"issue":"1","key":"2026080419562111400_zxag062-B46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00213-009-1635-z","article-title":"Effects of MDMA on sociability and neural response to social threat and social reward","volume":"207","author":"Bedi","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"issue":"1-2","key":"2026080419562111400_zxag062-B47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0304-3940(93)90565-3","article-title":"Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis","volume":"162","author":"Kawahara","year":"1993","journal-title":"Neurosci Lett"},{"key":"2026080419562111400_zxag062-B48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.pbb.2016.10.002","article-title":"MDMA (\u2018ecstasy\u2019), oxytocin and vasopressin modulate social preference in rats: a role for handling and oxytocin receptors","volume":"150-151","author":"Ramos","year":"2016","journal-title":"Pharmacol Biochem Behav"},{"issue":"9","key":"2026080419562111400_zxag062-B49","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1177\/0269881114542454","article-title":"Differential effects of MDMA and methylphenidate on social cognition","volume":"28","author":"Schmid","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"6","key":"2026080419562111400_zxag062-B50","doi-asserted-by":"publisher","first-page":"e0199384","DOI":"10.1371\/journal.pone.0199384","article-title":"Oxytocin receptor gene variations and socio-emotional effects of MDMA: a pooled analysis of controlled studies in healthy subjects","volume":"13","author":"Vizeli","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"2026080419562111400_zxag062-B51","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/17470919.2016.1143026","article-title":"Oxytocin receptor gene variation predicts subjective responses to MDMA","volume":"11","author":"Bershad","year":"2016","journal-title":"Soc Neurosci"},{"key":"2026080419562111400_zxag062-B52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.psyneuen.2014.04.006","article-title":"Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans","volume":"46","author":"Kirkpatrick","year":"2014","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"2026080419562111400_zxag062-B53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/0269881117699617","article-title":"Multifaceted empathy of healthy volunteers after single doses of MDMA: a pooled sample of placebo-controlled studies","volume":"31","author":"Kuypers","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"33","key":"2026080419562111400_zxag062-B54","doi-asserted-by":"publisher","first-page":"8230","DOI":"10.1523\/JNEUROSCI.1723-08.2008","article-title":"Intra-amygdala and systemic antagonism of NMDA receptors prevents the reconsolidation of drug-associated memory and impairs subsequently both novel and previously acquired drug-seeking behaviors","volume":"28","author":"Milton","year":"2008","journal-title":"J Neurosci"},{"issue":"44","key":"2026080419562111400_zxag062-B55","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J Neurosci"},{"issue":"10","key":"2026080419562111400_zxag062-B56","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/nn1778","article-title":"NMDA receptors are critical for unleashing consolidated auditory fear memories","volume":"9","author":"Ben Mamou","year":"2006","journal-title":"Nat Neurosci"},{"key":"2026080419562111400_zxag062-B57","doi-asserted-by":"publisher","first-page":"105044","DOI":"10.1016\/j.neuint.2021.105044","article-title":"Ketamine for post-traumatic stress disorders and it's possible therapeutic mechanism","volume":"146","author":"Asim","year":"2021","journal-title":"Neurochem Int"},{"issue":"9","key":"2026080419562111400_zxag062-B58","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.biopsych.2022.02.104","article-title":"Neural circuitry mechanisms of response to ketamine in PTSD: preliminary findings","volume":"91","author":"Feder","year":"2022","journal-title":"Biol Psychiatry"},{"issue":"6101","key":"2026080419562111400_zxag062-B59","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1126\/science.1223006","article-title":"Disruption of reconsolidation erases a fear memory trace in the human amygdala","volume":"337","author":"Agren","year":"2012","journal-title":"Science"},{"issue":"3","key":"2026080419562111400_zxag062-B60","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/s0896-6273(02)01001-2","article-title":"Cellular and systems reconsolidation in the hippocampus","volume":"36","author":"Debiec","year":"2002","journal-title":"Neuron"},{"issue":"6","key":"2026080419562111400_zxag062-B61","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/scan\/nsw031","article-title":"Resting-state functional connectivity between amygdala and the ventromedial prefrontal cortex following fear reminder predicts fear extinction","volume":"11","author":"Feng","year":"2016","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"7","key":"2026080419562111400_zxag062-B62","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.biopsych.2017.03.007","article-title":"It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD Psychopharmacology Working Group","volume":"82","author":"Krystal","year":"2017","journal-title":"Biol Psychiatry"},{"key":"2026080419562111400_zxag062-B63","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fnbeh.2016.00124","article-title":"Mindfulness-based stress reduction, fear conditioning, and the uncinate fasciculus: a pilot study","volume":"10","author":"Holzel","year":"2016","journal-title":"Front Behav Neurosci"},{"issue":"5","key":"2026080419562111400_zxag062-B64","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1503\/jpn.160129","article-title":"Decreased uncinate fasciculus tract integrity in male and female patients with PTSD: a diffusion tensor imaging study","volume":"42","author":"Koch","year":"2017","journal-title":"J Psychiatry Neurosci"},{"issue":"4","key":"2026080419562111400_zxag062-B65","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.tins.2020.11.008","article-title":"A dendrite-focused framework for understanding the actions of ketamine and psychedelics","volume":"44","author":"Savalia","year":"2021","journal-title":"Trends Neurosci"},{"issue":"5","key":"2026080419562111400_zxag062-B66","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/00952990.2023.2220874","article-title":"Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces veterans: prospective data from a clinical program in Mexico","volume":"49","author":"Davis","year":"2023","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"suppl 3","key":"2026080419562111400_zxag062-B67","doi-asserted-by":"publisher","first-page":"S718","DOI":"10.1037\/tra0001625","article-title":"Ayahuasca in the treatment of posttraumatic stress disorder: mixed-methods case series evaluation in military combat veterans","volume":"16","author":"Weiss","year":"2024","journal-title":"Psychol Trauma"},{"key":"2026080419562111400_zxag062-B68","doi-asserted-by":"publisher","first-page":"687615","DOI":"10.3389\/fpsyt.2021.687615","article-title":"Ceremonial ayahuasca in Amazonian retreats \u2014 mental health and epigenetic outcomes from a six-month naturalistic study","volume":"12","author":"Ruffell","year":"2021","journal-title":"Front Psychiatry"},{"issue":"10","key":"2026080419562111400_zxag062-B69","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1177\/02698811241273772","article-title":"A phase 1 single ascending dose study of pure oral harmine in healthy volunteers","volume":"38","author":"Ables","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"3","key":"2026080419562111400_zxag062-B70","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/ADM.0000000000000734","article-title":"Posttraumatic stress disorder after a psychedelic experience, a case report","volume":"15","author":"Rubin-Kahana","year":"2021","journal-title":"J Addict Med"},{"issue":"12","key":"2026080419562111400_zxag062-B71","doi-asserted-by":"publisher","first-page":"e2449026","DOI":"10.1001\/jamanetworkopen.2024.49026","article-title":"Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial","volume":"7","author":"Back","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026080419562111400_zxag062-B72","doi-asserted-by":"publisher","first-page":"863552","DOI":"10.3389\/fpsyt.2022.863552","article-title":"Using a MDMA- and LSD-group therapy model in clinical practice in Switzerland and highlighting the treatment of trauma-related disorders","volume":"13","author":"Oehen","year":"2022","journal-title":"Front Psychiatry"},{"key":"2026080419562111400_zxag062-B73","doi-asserted-by":"publisher","first-page":"119866","DOI":"10.1016\/j.jad.2025.119866","article-title":"Development of an Australian clinical practice guideline on methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder","volume":"391","author":"Yong","year":"2025","journal-title":"J Affect Disord"},{"issue":"4","key":"2026080419562111400_zxag062-B74","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/PRA.0000000000000091","article-title":"Benzodiazepines for PTSD: a systematic review and meta-analysis","volume":"21","author":"Guina","year":"2015","journal-title":"J Psychiatr Pract"},{"issue":"5","key":"2026080419562111400_zxag062-B75","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1682\/jrrd.2011.09.0183","article-title":"Pharmacotherapy for posttraumatic stress disorder: review with clinical applications","volume":"49","author":"Jeffreys","year":"2012","journal-title":"J Rehabil Res Dev"},{"issue":"1","key":"2026080419562111400_zxag062-B76","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"2026080419562111400_zxag062-B77","doi-asserted-by":"publisher","first-page":"E204","DOI":"10.1503\/cmaj.241191","article-title":"Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population","volume":"197","author":"Myran","year":"2025","journal-title":"CMAJ"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag062\/67241650\/zxag062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/16\/822\/67241650\/zxag062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/16\/822\/67241650\/zxag062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:56:28Z","timestamp":1785887788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/16\/822\/8507027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":77,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag062","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,15]]},"published":{"date-parts":[[2026,3,5]]}}}